Immatics and MDACC have created Immatics US, Inc. to develop multiple next generation adoptive cell therapies for the treatment of cancer
Immatics US, Inc. is developing multiple, next-generation Adoptive Cell Therapies (ACT) for the treatment of cancer. These therapies use human T-cells that have been multiplied outside the body before being infused into a cancer patient, where they recognize and kill tumor cells.
T-cells are a type of white blood cell that plays a central role in the immune system by recognizing antigens, typically presented on the surface of abnormal cells, and triggering an immune response.
Immatics is well positioned to become a global leader in ACT based on its cancer target discovery engine XPRESIDENT®. This platform enables the discovery of ACT targets from amongst the full array of proteins expressed by a cancer cell, including intra-cellular proteins not addressed by antibody and Chimeric Antigen Receptors (CAR) approaches.
Immatics US, Inc. is the only company globally working on three different ACT approaches using multiple proprietary cancer targets. These approaches aim to deliver a step change in the treatment of solid tumors against which current therapies deliver only limited clinical and survival benefits.
Pre-clinical development is well underway and clinical development of the company’s lead ACT is expected to commence in 2016.
Recent Highlighted News
Immatics at PEGS 2017 (May 1 - 5) in Boston, USA Immatics is looking forward to a fruitful discussion on target discovery approaches in Immuno-Oncology within the Immunotherapy Stream at this year’s PEGS 2017 in Boston. Friday, May 5 Novel Targets for Cancer...read more
Target Profiling for Cancer Immunotherapy: Immatics to present at BioEurope Spring® international life science partnering event 2017 (March 20-22, Barcelona, Spain)
Target Profiling for Cancer Immunotherapy: Immatics to present at BioEurope Spring® international life science partnering event 2017 (March 20-22, Barcelona, Spain) Date/ Time: Tuesday, March 21, 3.30pm - 3.45pm Immatics company presentation in Oncology Track We are...read more